Eli Lilly and Company (LLY)'s Experimental Diabetes Drug Helps Reduce Weight
6/24/2013 7:51:06 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Patients taking Eli Lilly & Co. (LLY)’s experimental diabetes drug dulaglutide lost weight and had side effects that were manageable, the company said today after releasing more data from three final-stage clinical trials. Lilly released top-line results from the company-sponsored trials last year, when it reported more patients taking the therapy had blood glucose levels indicating their disease was under control than those given Merck (MRK) & Co.’s top-selling drug Januvia and Bristol-Myers Squibb Co.’s Byetta. The data released today had details of those results, as well as side effect and weight-loss information. “We look at the space and we feel we have an opportunity to offer a significant new product,” said Sherry Martin, senior medical director for diabetes development at Indianapolis-based Lilly. The company plans to submit the drug to U.S. regulators for approval by the end of this year, she said. The studies were presented as part of the American Diabetes Association meeting in Chicago.
Help employers find you! Check out all the jobs and post your resume.